ATE550352T1 - Verfahren zur herstellung von hybridantikörper - Google Patents

Verfahren zur herstellung von hybridantikörper

Info

Publication number
ATE550352T1
ATE550352T1 AT02794114T AT02794114T ATE550352T1 AT E550352 T1 ATE550352 T1 AT E550352T1 AT 02794114 T AT02794114 T AT 02794114T AT 02794114 T AT02794114 T AT 02794114T AT E550352 T1 ATE550352 T1 AT E550352T1
Authority
AT
Austria
Prior art keywords
hybrid
antibodies
framework regions
hybrid antibodies
antibody fragments
Prior art date
Application number
AT02794114T
Other languages
English (en)
Inventor
Russell Rother
Dayang Wu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE550352T1 publication Critical patent/ATE550352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02794114T 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper ATE550352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
PCT/US2002/038450 WO2003048321A2 (en) 2001-12-03 2002-12-03 Hybrid antibodies

Publications (1)

Publication Number Publication Date
ATE550352T1 true ATE550352T1 (de) 2012-04-15

Family

ID=23316785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794114T ATE550352T1 (de) 2001-12-03 2002-12-03 Verfahren zur herstellung von hybridantikörper

Country Status (12)

Country Link
US (1) US7399594B2 (de)
EP (2) EP2298817A1 (de)
JP (3) JP4723810B2 (de)
AT (1) ATE550352T1 (de)
AU (1) AU2002359568B2 (de)
CA (1) CA2468744C (de)
CY (1) CY1112843T1 (de)
DK (1) DK1461428T3 (de)
ES (1) ES2384100T3 (de)
PT (1) PT1461428E (de)
SI (1) SI1461428T1 (de)
WO (1) WO2003048321A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
EP1521776A2 (de) * 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasma-spezifische antikörper und deren verwendungen
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
JP2007534307A (ja) * 2003-11-07 2007-11-29 キュラジェン コーポレイション 分泌性白血球プロテアーゼインヒビターに対する抗体
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
CA2550155C (en) * 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
WO2005098039A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
JP5597793B2 (ja) 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
EP2245064B1 (de) * 2007-12-21 2014-07-23 Medimmune Limited BINDUNGSELEMENTE FÜR INTERLEUKIN-4-REZEPTOR ALPHA (IL-4Ralpha)
CA2708074A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2356154A4 (de) * 2008-11-06 2012-12-19 Alexion Pharma Inc Synthetische antikörper mit verminderter immunogenität und herstellungsverfahren
EP2411050A4 (de) * 2009-03-25 2013-07-17 Vet Therapeutics Inc Antikörperregionen mit konstanter domäne und ihre verwendung
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109662A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
MX364329B (es) * 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
PL3638373T3 (pl) 2017-06-14 2025-04-14 Adc Therapeutics Sa Schematy dawkowania dla podawania ADC anty-CD19
EP3668874B1 (de) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepinkonjugate
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
EP0670905B1 (de) 1992-09-22 2003-07-23 Biofocus Discovery Limited Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1997034632A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Also Published As

Publication number Publication date
EP2298817A1 (de) 2011-03-23
JP2009153527A (ja) 2009-07-16
PT1461428E (pt) 2012-05-29
WO2003048321A3 (en) 2003-10-16
DK1461428T3 (da) 2012-06-04
JP5054058B2 (ja) 2012-10-24
ES2384100T3 (es) 2012-06-29
JP4723810B2 (ja) 2011-07-13
AU2002359568A1 (en) 2003-06-17
EP1461428B1 (de) 2012-03-21
CY1112843T1 (el) 2016-02-10
CA2468744C (en) 2013-05-14
US7399594B2 (en) 2008-07-15
JP2012144551A (ja) 2012-08-02
WO2003048321A2 (en) 2003-06-12
EP1461428A2 (de) 2004-09-29
JP2005511706A (ja) 2005-04-28
US20030219861A1 (en) 2003-11-27
CA2468744A1 (en) 2003-06-12
AU2002359568B2 (en) 2008-02-21
EP1461428A4 (de) 2005-05-25
SI1461428T1 (sl) 2012-07-31

Similar Documents

Publication Publication Date Title
ATE550352T1 (de) Verfahren zur herstellung von hybridantikörper
WO2004108889A3 (en) Hybrid antibodies
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
ITRM20030601A1 (it) Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DE69842174D1 (de) Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
ATE368095T1 (de) Verfahren zur herstellung von mitteldistillaten
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
IL213524A0 (en) Method for removing blood group antigens in serum
DE60232618D1 (de) Mikrofluidische Vorrichtung, Verfahren zur Herstellung und Verwendung desselben
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
ATE557040T1 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
DE60332111D1 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
ATE297430T1 (de) Verfahren zur herstellung von tannin und seine verwendung
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE423467T1 (de) Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
WO2023154814A3 (en) Shbg and ibp4 antibodies and methods using same
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof